Page results
-
Nine Covid-19 research studies are already taking place at UCLH and the Trust is processing more than 30 study proposals as research efforts around the virus and pandemic are ramped up.
-
UCLH is celebrating the delivery of its 1,000th respiratory syncytial virus (RSV) vaccine to pregnant women, following the rollout of the new national programme in September.
-
UCLH and UCL are at the forefront of Women’s Health care and research – across areas including reproductive health, maternity, breast care, care for newborns, gynaecological care, and cancer.
-
Our staff have rated UCLH as the top trust in London to work at, and the third best in the country, during what has been another incredibly challenging year.
-
While you're pregnant you will have a nominated professional lead which will be a midwife or an obstetrician.
-
UCLH Pain Management Centre is a nationally recognized centre of excellence for people with longstanding pain.
-
UCLH has declared a climate and health emergency, and has published a 10-point climate action plan to reach net zero carbon dioxide emissions by 2031.
-
UCLH has recruited the first patient in Europe for an early phase trial of a potential new medicine for patients that have a specific sub-type of multiple myeloma (MM), a type of bone marrow cancer.
-
The Royal National ENT Voice Centre is a national and international multidisciplinary centre for voice disorders. The voice clinic at the RNENT is one of the oldest in the UK.
-
North Mid, UCLH and Whittington Health are running a fun, uplifting, informative event for people with sickle cell on Saturday 25th June 2022.
File results
-
FOI/2022/0557 - Patients treated with Visudyne (verteporfin)
-
FOI/2022/0563 - Ambulatory cardiac monitoring
-
FOI/2022/0544 - Wards/ departments that provide services to 0-17 year-olds
-
FOI/2022/0545 - Criteria used in determining acceptance of GP referrals for osteoporosis treatment, and for priorisation of osteoporosis appointments
-
FOI/2022/0546 - Metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology
-
FOI/2022/0549 - SACT (systemic anti-cancer therapy) /cervical cancer treatments
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff